Ramos-Casals M., Soto MJ, Cuadrado MJ, Khamashta MARituximab in systemic lupus erythematosus. A systematic review of off-label use in 188 cases. Lupus2009; 18: 767-776.
2.
Sfikakis PP, Boletis JN, Lionaki S., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum2005; 52: 501-513.
3.
Ng KP, Cambridge G., Leandro MJ, Edwards JC, Ehrenstein M., Isenberg DAB cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis2007; 66: 1259-1262.
4.
Gunnarsson I. , Sundelin B., Jonsdottir T., Jacobson SH, Henriksson EW, van Vollenhoven RFHistopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum2007; 56: 1263-1272.
5.
van Vollenhoven RF, Gunnarsson I., Welin-Henriksson E., et al. Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol2004; 33: 423-427.
6.
Vigna-Perez M., Hernandez-Castro B., Paredes-Saharopulos O., et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther2006; 8: R83.
